Dongwha Pharm's comprehensive cold medicine, Pancold S, has taken the top spot in domestic cold medicine sales for the second consecutive year.

According to IQVIA’s MAT (moving annual total) data for the third quarter (from the fourth quarter of 2023 to the third quarter of 2024), Pancold S recorded sales of 35.8 billion won ($24.9 million), accounting for 25 percent of total 143 billion won cold medicine market.

It is the first time the brand has held the top spot for two years

Launched in 1968, Pancold is a general cold medicine containing acetaminophen, an antipyretic analgesic. It is marketed in three products: Pancold S, a cold medicine for adults sold in pharmacies, Pancold I-Cold Syrup for children, and Pancold A, a safety emergency medicine sold in convenience stores.

According to Dongwha Pharm’s tally, the total sales of Pancold products totaled 51.1 billion won last year.

“Pancold S is a representative cold medicine still loved even after 50 years since its launch,” a company official said. “We will continue to lead the cold medicine market by maintaining high quality and stability.”